Ascendis Pharma Is Maintained at Overweight by JP Morgan

Ascendis Pharma Is Maintained at Overweight by JP Morgan

Dow JonesMay 3 23:28

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower

European equities traded in the US as American depositary receipts were trending modestly higher Friday morning, rising 0.42% to 1,371.48 on the S&P Europe Select ADR Index. Despite the gain, the inde

MT NewswiresMay 3 23:11

Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald

Ascendis Pharma Price Target Maintained With a $173.00/Share by Cantor Fitzgerald

Dow JonesMay 3 23:09

Cantor Fitzgerald Corp.: Reiterates Ascendis Pharma (ASND.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of $173.00.

Cantor Fitzgerald Corp.: Reiterates Ascendis Pharma (ASND.US) rating and adjusted from an increase to an increase in holdings rating, with a target price of $173.00.

Zhitong FinanceMay 3 23:00

Ascendis Pharma Q1 Net Loss Widens, Revenue Rises

Ascendis Pharma (ASND) reported a Q1 net loss late Thursday of 2.30 euros ($2.47) per diluted share, compared with a loss of 1.98 euros a year earlier. Analysts polled by Capital IQ expected a per-sha

MT NewswiresMay 3 15:49

Ascendis Pharma Q1 Sales €95.894M Beat €79.492M Estimate

Ascendis Pharma Q1 Sales €95.894M Beat €79.492M Estimate

BenzingaMay 3 04:46